This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Lawrence L. Sanders, Jr, MD; H. Robert Harrison, DPhil, MD, MPH; A. Eugene Washington, MD

JAMA. 1986;255(13):1750-1756.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

RECOMMENDATIONS for treatment of infections caused by Chlamydia trachomatis were last established in 1982.¹ Since that time, studies have provided new information about the epidemiology and the clinical spectrum of the diseases associated with C trachomatis infections. In addition, new antimicrobial agents have become available and old agents have been studied more extensively in treatment trials. These recent developments prompt the need for an updated review of the treatment of these widespread infections.

Chlamydial infections are now recognized as the most common bacterial sexually transmitted diseases in the United States. An estimated 3 million people have infections caused by C trachomatis each year.²Chlamydia trachomatis is the leading cause of nongonococcal urethritis (roughly 50%) and of epididymitis in men younger than 35 years of age. In women, where the majority of infections are asymptomatic, C trachomatis infection causes mucopurulent cervicitis, urethral syndrome, and pelvic inflammatory disease (PID). . . . [Full Text PDF of this Article]

Author Affiliations
From the Division of Sexually Transmitted Diseases, Center for Prevention Services, Centers for Disease Control, Atlanta.

Footnotes
Reprint requests to Technical Information Services, Center for Prevention Services, Centers for Disease Control, Atlanta, GA 30333 (Dr Sanders).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?